Noticias de VIR_US

Mercado

Noticias del mercado

Últimas noticias sobre VIR_US — 219 novedades recientes. Análisis, balances, opiniones y cobertura de prensa.

Ticker: VIR_US ✕ 219 resultados
03/10/2026 VIR_US — Yahoo Finance
Vir Biotechnology, Inc. (VIR) Stock Forecasts

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

02/10/2026 VIR_US — The Globe and Mail
Vir Biotechnology Appoints Aziz Sawaf as New CFO

Información detallada de precios de Vir Biotechnology Inc (VIR-Q) de The Globe and Mail, incluidos gráficos y operaciones.

02/10/2026 VIR_US — Yahoo Finance
Vir Biotechnology, Inc. (VIR) Stock Forecasts

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

02/10/2026 VIR_US — Yahoo Finance
Vir Biotechnology, Inc. (VIR) Stock Forecasts

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

01/10/2026 VIR_US — Yahoo Finance
Vir Biotechnology, Inc. (VIR) Stock Forecasts

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

01/10/2026 VIR_US — AD HOC NEWS
Raymond James reiterates USD 19.00 target for Vir Biotechnology stock

Revenue hit USD 238.95 million in the second quarter, up 19,582.50 percent year over year. Vir Biote

01/10/2026 VIR_US — Contract Pharma
Vir Biotechnology Appoints Aziz Sawaf as EVP and CFO

Vir Biotechnology, Inc. has appointed Aziz Sawaf, MBEE, MBA, CFA, as Executive Vice President and Chief Financial Officer (CFO).

30/09/2026 VIR_US — MarketBeat
Vir Biotechnology, Inc. (NASDAQ:VIR) Stock Rated "Moderate Buy" by Sell-Side Brokerages

A las acciones de Vir Biotechnology, Inc. (NASDAQ:VIR - Obtenga el informe gratuito) se les ha asignado una calificación de consenso de "Compra moderada" por parte de las ocho firmas de calificación que actualmente cubren la acción, informa MarketBeat Ratings. Un analista de investigación calificó la acción con una recomendación de venta, seis la asignaron

29/09/2026 VIR_US — Kalkine Media
Vir Biotechnology (NASDAQ:VIR) Nears Key Hepatitis Delta Readout

Vir Biotechnology (NASDAQ:VIR) se prepara para los datos fundamentales de la hepatitis delta de ECLIPSE en el cuarto trimestre con una pista de efectivo fortalecida. Lea lo último.

Página 5 de 11